Literature DB >> 21252079

Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.

Yun Li1, Jeremy M G Taylor, Michael R Elliott, Daniel J Sargent.   

Abstract

When the true end points (T) are difficult or costly to measure, surrogate markers (S) are often collected in clinical trials to help predict the effect of the treatment (Z). There is great interest in understanding the relationship among S, T, and Z. A principal stratification (PS) framework has been proposed by Frangakis and Rubin (2002) to study their causal associations. In this paper, we extend the framework to a multiple trial setting and propose a Bayesian hierarchical PS model to assess surrogacy. We apply the method to data from a large collection of colon cancer trials in which S and T are binary. We obtain the trial-specific causal measures among S, T, and Z, as well as their overall population-level counterparts that are invariant across trials. The method allows for information sharing across trials and reduces the nonidentifiability problem. We examine the frequentist properties of our model estimates and the impact of the monotonicity assumption using simulations. We also illustrate the challenges in evaluating surrogacy in the counterfactual framework that result from nonidentifiability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252079      PMCID: PMC3114655          DOI: 10.1093/biostatistics/kxq082

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  18 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  The validation of surrogate endpoints in meta-analyses of randomized experiments.

Authors:  M Buyse; G Molenberghs; T Burzykowski; D Renard; H Geys
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

3.  Counterfactual links to the proportion of treatment effect explained by a surrogate marker.

Authors:  Jeremy M G Taylor; Yue Wang; Rodolphe Thiébaut
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

4.  Surrogate marker evaluation from an information theory perspective.

Authors:  Ariel Alonso; Geert Molenberghs
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

5.  Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective.

Authors:  Ariel Alonso; Geert Molenberghs
Journal:  Stat Methods Med Res       Date:  2008-02-19       Impact factor: 3.021

6.  Information theory-based surrogate marker evaluation from several randomized clinical trials with binary endpoints, using SAS.

Authors:  Abel Tilahun; Assam Pryseley; Ariel Alonso; Geert Molenberghs
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

7.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

8.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

9.  End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Authors:  Daniel J Sargent; Smitha Patiyil; Greg Yothers; Daniel G Haller; Richard Gray; Jacqueline Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; David Kerr; Erin Green; Harry S Wieand; Richard M Goldberg; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

10.  Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials.

Authors:  Julian Wolfson; Peter Gilbert
Journal:  Biometrics       Date:  2010-12       Impact factor: 2.571

View more
  7 in total

1.  Surrogate endpoint analysis: an exercise in extrapolation.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2012-12-21       Impact factor: 13.506

2.  Evaluation and comparison of predictive individual-level general surrogates.

Authors:  Erin E Gabriel; Michael C Sachs; M Elizabeth Halloran
Journal:  Biostatistics       Date:  2018-07-01       Impact factor: 5.899

3.  Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling.

Authors:  Ying Huang
Journal:  Biometrics       Date:  2017-06-26       Impact factor: 2.571

4.  Bayesian inference for the causal effect of mediation.

Authors:  Michael J Daniels; Jason A Roy; Chanmin Kim; Joseph W Hogan; Michael G Perri
Journal:  Biometrics       Date:  2012-09-24       Impact factor: 2.571

5.  Design and estimation for evaluating principal surrogate markers in vaccine trials.

Authors:  Ying Huang; Peter B Gilbert; Julian Wolfson
Journal:  Biometrics       Date:  2013-02-14       Impact factor: 2.571

6.  Accommodating missingness when assessing surrogacy via principal stratification.

Authors:  Michael R Elliott; Yun Li; Jeremy M G Taylor
Journal:  Clin Trials       Date:  2013-04-03       Impact factor: 2.486

Review 7.  Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments.

Authors:  Christopher J Weir; Rod S Taylor
Journal:  Pharm Stat       Date:  2022-07       Impact factor: 1.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.